Tags

Type your tag names separated by a space and hit enter

The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
Horm Metab Res. 1992 Jul; 24(7):329-32.HM

Abstract

Growth hormone (GH) hypersecretion is well documented in insulin-dependent diabetes mellitus (IDDM). Somatostatin inhibits GH in acromegalics and healthy subjects although data on its inhibitory effects on high GH levels in IDDM patients are controversial. The effect of treatment with the somatostatin analogue octreotide ("Sandostatin") on GH secretion, IGF1 levels and metabolic control was investigated in insulin-dependent diabetics. Growth hormone and blood glucose were measured at hourly intervals whilst IGF-I was measured every 6 hours during the 24-h period before and after 7 days' treatment with octreotide (200 micrograms subcutaneously three times daily) in 10 C-peptide negative diabetics. Octreotide significantly reduced mean 24 h GH profile (7.2 +/- 0.7 mU/L before; 5.2 +/- 0.5 mU/L on octreotide, p less than 0.01), IGF-I levels (0.62 +/- 0.06 before; 0.47 +/- 0.05 on octreotide, p less than 0.005) mean 24 h blood glucose (14.4 +/- 0.5 mmol/L before; 12.6 +/- 0.4 mmol/L on octreotide, p less than 0.001) and daily insulin requirements (44.8 +/- 3.0 IU before; 37.2 +/- 3.0 IU on octreotide, p less than 0.02). The shape of 24 h GH profile curve changed significantly on octreotide treatment (p less than 0.05) when it consisted of three nadirs and three peaks closely linked with the time of octreotide administration. Moderate (abdominal discomfort) to severe hypoglycaemia) transient side effects have been observed in all treated patients. The results of this study showed that short-term treatment with octreotide given s. c. every eight hours modulates the pattern of GH secretion in C-peptide negative insulin-dependent patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Wurzburger MI
Endocrinology Department, University Medical Centre Zvezdara, Belgrade, Yugoslavia.
Prelevic GM
No affiliation info available
Sonksen PH
No affiliation info available
Balint-Peric LA
No affiliation info available

MeSH

AdultBlood GlucoseC-PeptideDiabetes Mellitus, Type 1Growth HormoneHumansInsulinInsulin SecretionInsulin-Like Growth Factor IOctreotide

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1516889

Citation

Wurzburger, M I., et al. "The Effect of the Somatostatin Analogue Octreotide On Growth Hormone Secretion in Insulin-dependent Diabetics Without Residual Insulin Secretion." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 24, no. 7, 1992, pp. 329-32.
Wurzburger MI, Prelevic GM, Sonksen PH, et al. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion. Horm Metab Res. 1992;24(7):329-32.
Wurzburger, M. I., Prelevic, G. M., Sonksen, P. H., & Balint-Peric, L. A. (1992). The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 24(7), 329-32.
Wurzburger MI, et al. The Effect of the Somatostatin Analogue Octreotide On Growth Hormone Secretion in Insulin-dependent Diabetics Without Residual Insulin Secretion. Horm Metab Res. 1992;24(7):329-32. PubMed PMID: 1516889.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion. AU - Wurzburger,M I, AU - Prelevic,G M, AU - Sonksen,P H, AU - Balint-Peric,L A, PY - 1992/7/1/pubmed PY - 1992/7/1/medline PY - 1992/7/1/entrez SP - 329 EP - 32 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 24 IS - 7 N2 - Growth hormone (GH) hypersecretion is well documented in insulin-dependent diabetes mellitus (IDDM). Somatostatin inhibits GH in acromegalics and healthy subjects although data on its inhibitory effects on high GH levels in IDDM patients are controversial. The effect of treatment with the somatostatin analogue octreotide ("Sandostatin") on GH secretion, IGF1 levels and metabolic control was investigated in insulin-dependent diabetics. Growth hormone and blood glucose were measured at hourly intervals whilst IGF-I was measured every 6 hours during the 24-h period before and after 7 days' treatment with octreotide (200 micrograms subcutaneously three times daily) in 10 C-peptide negative diabetics. Octreotide significantly reduced mean 24 h GH profile (7.2 +/- 0.7 mU/L before; 5.2 +/- 0.5 mU/L on octreotide, p less than 0.01), IGF-I levels (0.62 +/- 0.06 before; 0.47 +/- 0.05 on octreotide, p less than 0.005) mean 24 h blood glucose (14.4 +/- 0.5 mmol/L before; 12.6 +/- 0.4 mmol/L on octreotide, p less than 0.001) and daily insulin requirements (44.8 +/- 3.0 IU before; 37.2 +/- 3.0 IU on octreotide, p less than 0.02). The shape of 24 h GH profile curve changed significantly on octreotide treatment (p less than 0.05) when it consisted of three nadirs and three peaks closely linked with the time of octreotide administration. Moderate (abdominal discomfort) to severe hypoglycaemia) transient side effects have been observed in all treated patients. The results of this study showed that short-term treatment with octreotide given s. c. every eight hours modulates the pattern of GH secretion in C-peptide negative insulin-dependent patients.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/1516889/The_effect_of_the_somatostatin_analogue_octreotide_on_growth_hormone_secretion_in_insulin_dependent_diabetics_without_residual_insulin_secretion_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓3]

Related Citations

More